N onsteroidal anti-inflammatory drugs ameliorate pain, fever, and inflammation by inhibiting COX (cyclooxygenase; 2 major isomers identified as COX-1 and COX-2)-the rate-limiting enzyme in the synthetic cascade of prostanoids. 1 Clinical evidence shows that Nonsteroidal anti-inflammatory drugs selective for COX-2 inhibition increase cardiovascular thrombotic events. [2] [3] [4] This is attributable to suppression of COX-2-derived PGI 2 (prostacyclin).
plus clopidogrel after percutaneous coronary intervention. 13 However, a follow-up trial confirmed an increased thrombotic risk with celecoxib, despite the dual antiplatelet therapy, 14 which limits its clinical application. Tissue-specific deletion of mPGES-1-the underlying alternative target for COX-2-in endothelial cells (ECs) or vascular smooth muscle cells (SMCs) enhances neointima formation, whereas myeloid cell mPGES-1 deletion reduces vascular hyperplasia response to injury. 15 Our previous study shows that deletion of mPGES-1 attenuates injury-induced neointimal formation in mice, with sustained reduction in PGE 2 (prostaglandin E 2 ) and augmentation in PGI 2 . 16 PGI 2 signaling via the IP is known to restrain the neointimal formation. 17 In contrast to IP deletion, deletion of the thromboxane A 2 receptor depresses this response. 17 The role of mPGES-1-derived PGE 2 in the vascular remodeling that is independent of the IP signaling remains unknown. PGE 2 has 4 G protein-coupled receptors, EP (E prostanoid receptor) 1 through EP4, which mediates differential downstream signaling. 18 EP3 mediates vascular SMC migration facilitating neointimal hyperplasia in mice. 19 EP4 protects against ischemia-reperfusion injury, 20, 21 hypertension, 22 or atherosclerosis. 23 EP4 promotes endothelial migration and angiogenesis. 24, 25 However, whether EP4 regulates injuryinduced neointimal formation is unknown.
Here, we report that removal of the IP receptor uncovers a protective role of mPGES-1-derived PGE 2 in endothelial repair and the vascular response to injury. Furthermore, deletion of endothelial EP4 exacerbates, whereas pharmacological activation of EP4 limits, neointimal hyperplasia after wire injury.
Materials and Methods

Animal Study
Mice deficient in mPGES-1 (gene: Ptges) 26 and IP (gene: Ptgir) 17 were obtained from Pfizer and the FitzGerald Laboratory at the University of Pennsylvania, respectively. Both strains had been backcrossed to a C57BL/6 background for >10 generations and were used to derive IP/mPGES- with Ptgir −/− Ptges +/− . DKO mice develop normally without overt abnormalities. Global deletion of EP4 is perinatally lethal because of patent ductus arteriosus. 27 To circumvent this defect, endothelial-specific EP4 (gene: Ptger4) KO mice were generated using a tamoxifen-CreERT2 strategy. 28 Briefly, C57BL/ Cdh5-CreERT2 + ) and littermate controls (Ptger4 f/f Cdh5-CreERT2 − ). To induce endothelial EP4 deletion, tamoxifen (37.5 mg/mL dissolved in sunflower seed oil) was intraperitoneally injected into the experimental mice and littermate controls at a dose of 150 mg/kg per day for 6 days, which was interrupted for 3 days after the third dose. Gene-modified mice used in this study were sex matched. The pooled data from both sexes were used to show the gene-specific effects in each study, and sex-specific subgroup analyses were provided in Tables I and II in the online-only Data Supplement. Male C57BL/6 mice aged 6 to 8 weeks from the National Institutes for Food and Drug Control (Beijing, China) were used to determine the effect of AE1-329 (gifted by ONO Pharmaceutical Co, Ltd, Osaka, Japan) or misoprostol (410004; purity, 98.9%; National Institutes for Food and Drug Control, Beijing, China) in vascular remodeling. All animal protocols were performed following the guidelines of the Institutional Animal Care and Use Committee, the Experimental Animal Center, Fuwai Hospital, National Center for Cardiovascular Diseases, China.
Femoral Artery Injury Model
Femoral arteries were injured using a protocol as we described previously. 28 Briefly, a groin incision was made on 1 side of the anesthetized mouse. The femoral artery and its small branch between the rectus femoris and vastus medialis muscles were then carefully exposed and separated from the accompanying nerve and vein via blunt dissection. A 6-0 silk suture was then looped round the proximal femoral artery to stop the blood flow during the surgery. Another 6-0 silk suture was placed under the branch. A transverse arteriotomy was then made in the branch, and a flexible angioplasty wire (0.35 mm diameter; Cook, Inc, IN) was inserted into the femoral artery from the branch for a length no less than 5 mm toward the iliac artery. The wire was left in place for 3 minutes to dilate and denude the artery. Then, the wire was removed, the branch was ligated proximally with the 6-0 silk suture, and the blood flow in the femoral artery was restored by releasing the sutures for blood flow control. The skin incision was then closed with a 5-0 silk suture. Seven or 28 days after injury, the arteries were harvested, embedded in paraffin, and stained with hematoxylin and eosin for determination of the severity of hyperplasia. In detail, cross sections of the arteries were serially obtained for 10 to 13 levels at 150-µm intervals, and the sections with the most severe hyperplasia were used for comparisons. To evaluate reendothelialization, the sections from the arteries 7 days post-injury were immunostained with vWF (von Willebrand factor)-an EC marker-and photographed with a charge-coupled device camera coupled to a microscope system (AXI0; Zeiss, Oberkochen, Germany). The segments along the vascular inner wall that were positive in vWF and the peripheral length of the vascular inner wall were measured using Image-Pro Plus 6.0 software (Media Cybernetics, MD). The ratio of the total length of the vWF-positive segments to the peripheral length was calculated to represent the extent of reendothelialization. To evaluate leukocytes infiltration/migration, representative sections from the arteries injured for 7 days were analyzed with hematoxylin and eosin staining. Briefly, after capturing the images, intima leukocytes were objectively determined using a hue, saturation, and intensity-based color selection strategy using Image-Pro Plus 6.0 software (Media Cybernetics, MD). 
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Cell Study
Endothelial Cells
Mouse aorta ECs (MAECs) were isolated as described previously. 28, 31 Briefly, aortas were harvested and cut into 1 to 2 mm 2 sections. The aortic segments were attached to a petri dish by their luminal side and were then cultured in a DMEM medium containing 20% fetal bovine serum (FBS) and 100 µg/mL EC growth supplement for 5 to 7 days, to allow the outgrowth of ECs. Then, the ECs were passaged and cultured. MAECs in passages 2 to 6 were used in this study. EC proliferation was compared in MAECs isolated from IP KO or DKO, in passage 2. Primary human microvascular ECs were brought from ScienCell (6000; Carlsbad, CA) and cultured in the same medium as that for MAEC culture.
Smooth Muscle Cells
Mouse aorta SMCs were isolated from IP KOs and DKOs. Briefly, aortas were isolated, scratched 3 times on the inner surfaces, and cut into 1 to 2 mm 2 sections. The aortic segments were then attached to a petri dish by their luminal side, covered by a cover slid, and cultured in a DMEM medium containing 10% FBS for 5 to 7 days. The mouse aorta SMCs were then passaged and cultured. Proliferation of mouse aorta SMCs in passage 2 was compared.
Cell Proliferation
Cell growth was determined with a cell counting kit-8 (40203ES60; Yeasen, Shanghai, China), following the manufacturer's instructions, as described previously. 28 The assay allows multiple detection without obvious cell toxicity. Briefly, the cells were seeded onto a 96-well flat-bottomed plate. After the cells were attached, ECs were cultured in the medium containing 3% FBS for 6 to 8 hours. Afterward, the culture medium was replaced with a 3% FBS medium-cell counting kit-8 mixture (10:1 in volume). Thereafter, the cells were cultured in the mixture for no longer than 4 hours; absorbance at 450 nm was determined as the baseline. Then the cells were cultured in fresh 3% FBS medium with the indicated reagents for another 48 hours. The culture medium was then replaced by the medium-cell counting kit-8 mixture, and the culture continued for the same time as above for determination of the absorbance at 450 nm. The change in absorbance between the 2 measurements was used to define the cell growth. To determine mouse aorta SMC proliferation, cells were prestarved in FBS-free serum for 24 hours, and then cultured in a medium containing 1% FBS, with 2 sequential incubations with cell counting kit- 
Endothelium-Leukocyte Adhesion Study
For endothelium-leukocyte adhesion assay, MAECs were seeded into the 96-well plate, prestarved in the DMEM containing 3% FBS for 6 to 8 hours, and incubated with tested reagents for 2 hours. Leukocytes were gathered from mouse peritoneal. Briefly, 4% Brewer-modified thioglycollate medium (211716; BD Biosciences, NJ) was injected into the mouse peritoneal (1 mL per mouse). Four to 5 hours later, the peritoneal leukocytes were washed out with 0.1% bovine serum albumin, centrifuged, and resuspended in the 1640 medium containing 10% FBS. When the preparation of ECs was completed, the culture medium with indicated drugs was replaced by the 1640 medium containing leukocytes (3×10 4 per well). ECs and leukocytes were then cocultured for 30 minutes. Later, the cells were rinsed once with 1640 medium containing rhodamine 6G (200 µg/mL; 252433; Sigma, Darmstadt, Germany), followed by 3 washes with fresh 1640 medium. The fluorescent signals were finally detected by a microplate reader (excitation wavelength, 560 nm; emitter wavelength, 560 nm; Infinite M200; Tecan, Hombrechtikon, Switzerland). The reagents and their concentrations used in this study were as follows: misoprostol (10 μmol/L; 410004; National Institutes for Food and Drug Control, Beijing, China), AE1-329 (1 μmol/L; gifted by ONO Pharmaceutical Co, Ltd, Osaka, Japan), GW627368X (1 μmol/L; HY-16963; MedChemExpress, NJ), and dbcAMP (30 μmol/L; D0260; Sigma, Darmstadt, Germany).
Immunofluorescence Staining
Immunofluorescence staining was performed following the same protocol as we described previously. 28 Briefly, the paraffin sections (5 μm) were deparaffinized, rehydrated, and subjected to antigen retrieval using an EDTA antigen-retrieval water (PH 9.0; ZSGB-BIO, Beijing, China). After 1-hour incubation with normal goat serum at room temperature, the samples were incubated with primary antibodies overnight at 4°C and subsequently stained with Alexa Fluor-488-coupled or Alexa Fluor-594-coupled secondary antibodies for 3 hours at room temperature. The sections were then mounted with a VectaShield medium containing DAPI (4',6-diamidino-2-phenylindole) to stain nuclei and imaged using a Zeiss microscope system (AXI0; Zeiss) or a laser-scanning confocal microscope system (SP8; Leica). For determination of reendothelialization, images were analyzed using Image-Pro Plus 6.0 software (Media Cybernetics, Inc, Rockville, MD). The primary antibodies and dilution fold used in the study were polyclonal anti-EP4 antibody (2.5 µg/mL; 101775; Cayman Chemical, MI), rabbit polyclonal anti-vWF antibody (1 µg/mL; F3520; Sigma, Darmstadt, Germany), sheep polyclonal anti-vWF antibody (10 µg/mL; Ab11713; Abcam, Cambridge, United Kingdom), monoclonal anti-α-SMA (smooth muscle actin) antibody (5 µg/mL; A5228; Sigma, Darmstadt, Germany), and polyclonal anti-F4/80 antibody (2 µg/mL; Ab16911; Abcam, Cambridge, United Kingdom).
Western Blot Analysis
For Western blot analysis, the cells were lysed in a RIPA buffer that contained protease inhibitors (4693116001; Roche, Basel, Switzerland). After centrifugation (15800 g, 10 minutes), cell lysates were mixed with a loading buffer, fractionated with 10% SDS-PAGE, and transferred onto polyvinylidene fluoride membranes. The membranes were then probed with the primary polyclonal antibodies against EP4 (2.5 µg/mL; 101775; Cayman, MI) overnight at 4°C, followed by incubation with goat anti-rabbit secondary antibody for 1 hour at room temperature. Finally, the membranes were incubated with enhanced chemiluminecence liquid (P1020; Applygen Technologies Inc, Beijing, China), and signals from immunoreactive bands were visualized using a FluorChem System (ProteinSimple, CA).
Prostanoid Determination
PGE 2 and PGI 2 levels were determined via measuring their major urinary metabolites, tetranor-PGEM and 2,3-dinor-6-keto-PGF1α by liquid chromatography-tandem mass spectrometry, as described previously.
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Statistical Analysis
Statistical analysis was performed using GraphPad Prism 5 software (GraphPad Software, Inc, San Diego, CA). When only 2 groups were involved, Student 2-tailed unpaired t test was used for comparison. Comparisons of multiple groups were made using a 1-way ANOVA analysis. Tukey or Bonferroni post hoc tests were performed for the data with equal variances, whereas Dunnett post hoc tests were used for data with unequal variances. And Bartlett tests were used for analyzing the variances of data. Results are expressed as mean±SEM. Differences were considered statistically significant at P<0.05.
Results
mPGES-1-Derived PGE 2 Protects Against Wire Injury-Induced Neointimal Formation in IP-Deficient Mice
Deletion of mPGES-1 in mice enhances PGI 2 production, which leads to the attenuated vascular remodeling. 16 To elucidate a role of mPGES-1-derived PGE 2 in vascular remodeling, we crossed mPGES-1 KOs with IP KOs to generate DKO mice and littermate IP KO mice as control. The mice were subjected to wire injury (endothelial denudation) of the femoral artery for 28 days. On this IP-deficient background, mPGES-1 deletion increased neointima area by ≈84% and also increased the ratio of intimal-to-medial area, with media thickness unaltered ( Figure 1A through 1D ). This reveals a protective role of mPGES-1-derived PGE 2 in the vascular response to injury. Urinary metabolite of PGE 2 was reduced in DKO mice, whereas PGI 2 metabolite was enhanced ( Figure 1E and 1F) .
To explore the underlying mechanism, vessels were harvested at 7 days after surgery for histology examination. Again, the neointimal area and the ratio of intima to media, but not the medial area, were significantly enhanced in DKO (Figure 2A and 2B) . Intima leukocytes, mainly macrophages (positive for F4/80 staining), were increased in the DKOs (Figure 2C and 2D; Figure I in the online-only Data Supplement). Expression of α-SMA was mainly detected in SMCs in the media, but rarely detected in the neointima area regardless genotypes ( Figure 2E ). When vWF (an endothelial marker) was stained, a striking reduction in the number of ECs was observed in the DKOs ( Figure 2D and 2F) , reflecting suppressed reendothelialization after the wire denudation injury.
To pursue a potential impact on endothelial repair, ECs were isolated from IP KOs and DKOs, and their capacity for proliferation was evaluated in vitro ( Figure 2G ). The EC proliferation was significantly impaired in the DKOs (Figure 2H) , revealing a proliferative effect of PGE 2 signaling in ECs. Further, treatment of ECs with misoprostol-a PGE (prostaglandin E) analogue-promoted EC proliferation in vitro ( Figure 2I ) and also decreased leukocyte adhesion to endothelial monolayer in vitro ( Figure 2J ).
Primary aortic SMCs were also isolated from IP KOs and DKOs. No difference in cell proliferation was detected between the 2 groups ( Figure II in the online-only Data Supplement).
EP4 Activation Promotes EC Proliferation and Reduces Endothelium-Leukocyte Adhesion
Receptors that might mediate the effect of PGE 2 on EC proliferation were then studied in vitro. ECs from DKO mice were treated with agonists 33, 34 for the EP1/3 (sulprostone, EC50=0.42 nmol/L for EP3, also a weak agonist for EP1), EP2 (butaprost, EC50=32 nmol/L), or EP4 (AE1-329, EC50=3.1 nmol/L) receptors, all at a concentration of 1 μmol/L. AE1-329, but not sulprostone or butaprost, promoted proliferation in the DKO ECs ( Figure 3A) . Similar effects were observed with wild-type ECs ( Figure 3B ). We further tested each drug at mutiple concentrations for cell proliferating activity ( Figure III in the online-only Data Supplement). AE1-329 dose dependently promoted EC proliferation, whereas butaprost showed a proproliferative effect at a higher concentration, that is, 10 μmol/L. AE1-329 enhanced EC proliferation in either absence or presence of IL (interleukin)-1β-a stimulus to PGE 2 production ( Figure 3C ; Figure IVA in the online-only Data Supplement). Conversely, GW627368X (a selective EP4 antagonist) markedly inhibited EC proliferation under IL-1β stimulation ( Figure 3D ). When mPGES-1 KO ECs were used, where PGE 2 production was depressed ( Figure  IVB in the online-only Data Supplement), the effect of EP4 agonism, but not that of EP4 antagonism, remained significant ( Figure 3E ). Thus, endogenous PGE 2 derived from EC mPGES-1 plays an active role in promoting proliferation of the IL-1β-stimulated ECs, which can be blocked by antagonism of EP4 but not of other EPs ( Figure 3F ). This further confirms the proliferative effect of EP4 activation in ECs ( Figure 3A and 3B) .
To elucidate EP4 downstream signaling, SQ22536 (an AC [adenylyl cyclase] inhibitor), H 89 2HCl (a PKA inhibitor), and ESI-09 (an EPAC [exchange protein activated by cAMP] inhibitor) were used. Treatment with SQ22536 or H 89 2HCl, but not with ESI-09, abrogated the proproliferation effect of AE1-329 ( Figure 3G ) and the anti-proliferation effect of GW627368X ( Figure 3H ), ) mice were subjected to wire injury at femoral arteries, and the vessels were harvested at 28 d after injury and quantified for neointima formation. Representative images of hematoxylin and eosin staining are shown (A; bar=100 μm). Neointimal area (B), ratio of intima to media (C), and media thickness (D) were determined (n=14 IPKO and 16 DKO). PGE 2 (E) and PGI 2 (prostacyclin; F) metabolites in urine were determined by HPLC-MS/MS as detailed in the Methods (n=8). Student unpaired t test. N.S. indicates nonsignificant. *P<0.05.
indicating that cAMP-PKA axis underlies the enhanced EC proliferation driven by EP4 activation. Consistent with this finding, Db-cAMP (a cell-permeable cAMP analogue) and forskolin (a potent AC activator) both promoted EC proliferation, and such proliferative effects were blunted by PKA inhibition with H89 2HCl or PKI ( Figure 3I ; Figures V and VI in the online-only Data Supplement). PGI 2 is known to elevate cAMP signaling via IP receptor. 1 Indeed, iloprost (1 μmol/L)-an IP agonist-promoted endothelial proliferation, whereas Cay10441 (10 μmol/L)-an IP antagonist-inhibited this response ( Figure 3J) , indicating a proliferative effect of PGI 2 on ECs.
The effect of EP4 on endothelium-leukocyte adhesion was also studied in vitro. Incubation of a monolayer of ECs with AE1-329-the EP4 selective agonist-significantly suppressed endothelium-leukocyte adhesion, whereas inhibition of endothelial EP4 by GW627368X enhanced the leukocyte adhesion to ECs ( Figure 3K ). This is consistent with a cAMP-mediated effect because Db-cAMP (a cell-permeable cAMP analogue, 30 μmol/L) treatment similarly reduced the leukocyte adhesion ( Figure 3L ). Deletion of mPGES-1 (microsomal prostaglandin E synthase-1) suppresses reendothelialization after endothelial denudation injury in IP (I prostanoid receptor)-deficient mice. Injured femoral arteries of DKO (double knockout) and IPKO (I prostanoid receptor knockout) were harvested at 7 d after surgery. Neointima formation and leukocyte infiltration were evaluated on hematoxylin and eosin (H&E) stained sections, with representative H&E images shown (A; bar=100 μm). Neointimal area, ratio of intima to media, and media thickness were quantified (B; n=14 IPKO and 16 DKO). The number of neointima leukocytes was quantified by analyzing the H&E stained tissue sections with Image-Pro Plus software (C; n=8 IPKO and 10 DKO). Injured vessels were immunostained for F4/80 (a marker of macrophage, red) and vWF (von Willebrand factor; an endothelial cell [EC] marker, green; D; bar=100 μm) and for α-SMA (α-smooth muscle actin; a smooth muscle cell marker; E; bar=100 μm). DAPI (4',6-diamidino-2-phenylindole) stains nuclei in blue. The number of vWF-positive cells was quantified to determine reendothelialization (F; n=7). ECs were isolated from the descending aortae of IPKO and DKO mice, and their cell proliferation was analyzed in vitro (G) and compared (H). Calculation of the EC proliferation rate was based on the difference in cell number before vs after treatment with 3% fetal bovine serum (FBS) for 48 h. Misoprostol-a PGE (prostaglandin E) analogue at 10 μmol/L-promoted endothelial proliferation (I; n=9 from 2 independent experiments) and inhibited endothelium-leukocyte adhesion (J; n=9 from 3 independent experiments). Student unpaired t test. CCK-8 indicates cell counting kit-8; and N.S, nonsignificant. *P<0.05, **P<0.01.
Endothelium-Restricted Deletion of EP4 Impairs Reendothelization and Exacerbates Neointimal Formation
The role of endothelial EP4 in vascular remodeling was then examined in mice deficient in this receptor only in ECs ( Figure 4A ) as confirmed by significant suppression of EP4 protein expression in ECs ( Figure 4B and 4C) . The mice were subjected to the wire injury and studied 28 days later. The neointimal area and the ratio of intimal-to-medial area were both enhanced in the mice lacking endothelial EP4, while the medial area was unchanged ( Figure 4D through 4G) . Seven days after vascular injury, reendothelialization was significantly suppressed in mice lacking EP4 only in ECs ( Figure 5A and 5B). This coincided with an increase in the number of intimal leukocytes and enhanced neointimal formation in cKOs ( Figure 5C through 5E).
EP4 Activation Protects Against Wire Injury-Induced Neointimal Formation
Systemic administration of AE1-329-the EP4 agonistalso ameliorated neointimal formation without affecting media thickness (Figure 6A and 6B) . Misoprostol, which promotes endothelial proliferation in vitro (Figure 2I ), 
EP4 Critically Involves in Human EC Proliferation
Activation of EP4 by AE1-329, but not of other EPs, promoted proliferation of human primary ECs ( Figure 7A ). Conversely, among antagonists of the 4 EPs, only EP4 blockade by GW627368X inhibited the EC proliferation ( Figure 7B ).
Discussion
Here, we report a novel mechanism that regulates vascular responses to injury in mice: PGE 2 acts via endothelial EP4 to promote reendothelialization and restrain neointimal formation after wire-induced vascular injury. A similar mechanism promotes proliferation of human ECs in vitro. These and cKO (endothelial EP4 conditional knockout) mice were harvested at 7 d after wire injury. Endothelial cells were immunostained for vWF (von Willebrand factor; green) and quantified for vascular coverage (reendothelialization; A and B, respectively; n=7 Ctl and 6 cKO). Neointimal formation and leukocyte infiltration were evaluated with hematoxylin and eosin (H&E) staining. The number of neointimal leukocytes was quantified (C; n=8 Ctl and 9 cKO). Representative H&E images are shown (D; bar=100 μm). Neointimal area, ratio of intima to media, and media thickness were statistically quantified (E; n=8). DAPI (4',6-diamidino-2-phenylindole) stains nuclei in blue. Student unpaired t test. N.S. indicates nonsignificant. *P<0.05.
observations raise the possibility that EP4 agonists may have value as adjunctive therapy in patients undergoing percutaneous revascularization.
We have previously reported that augmented biosynthesis of PGI 2 explains the reduced neointimal response to injury in mPGES-1 KO, raising the possibility that inhibitors of this enzyme will have a more favorable cardiovascular profile than nonsteroidal anti-inflammatory drugs targeting COX-2 that depress PGI 2 biosynthesis. 16 Here, removal of the PGI 2 receptor reveals a second therapeutic opportunity because mPGES-1-derived PGE 2 can limit neointimal formation after vascular injury (Figures 1 and  2) . Indeed, we show in mice that pharmacological activation of EP4 confers protection against the injury-induced intima hyperplasia ( Figure 6 ). Mechanistically, these beneficial effects are at least mediated through a support of EC repair by mPGES-1-derived PGE 2 and EP4 (Figures 2  and 6 ). We also observed an increased leukocyte infiltration ( Figure 2C ). This is consistent with a suppressing effect of EP4 activation on leukocyte adhesion ( Figures 2J  and 3K ). Previous studies 22, [35] [36] [37] [38] [39] indicate that the PGE 2 / EP4 axis inhibits mobilization of inflammatory cells and their response to inflammation. These studies highlight a possible contribution of the PGE 2 /EP4 axis on bone marrow microenvironment and on inflammatory cells per se in mediating the increased leukocyte infiltration to the injured vessels observed in the present study. Here, we discovered that EP4 in the endothelial compartment also mediates endothelial-leukocyte adhesion ( Figure 5 ). There was no discernible difference in the neointimal SMCs ( Figure 2E ) or in the proliferation of vascular SMCs isolated from the mPGES-1-deficient mice ( Figure II in the online-only Data Supplement). In cultured ECs, activation of EP4 (and perhaps EP2 but not EP1 and EP3), via cAMP-PKA pathway, promotes endothelial proliferation in vitro (Figure 3) , consistent with the observed suppression of neointimal formation after injury by such ligands in vivo. In line with this mechanistic hypothesis, deletion of the endothelial EP4 impaired reendothelialization and exacerbated neointimal formation after injury (Figures 4 and 5) . Furthermore, EP4 activation promoted reendothelialization and inhibited neointima formation in mice ( Figure 6 ). Therefore, EC EP4-mediated endothelial repair underscores a key mechanism that restrains the vascular hyperplasia after denudation injury. Promotion of endothelialization by activating endothelial EP4 represents a novel strategy to limit restenosis after percutaneous coronary intervention. 40 The mechanism of mPGES-1-derived PGE 2 in vascular remodeling is schematically illustrated in Figure VIII in the online-only Data Supplement.
Development of mPGES-1 inhibitors has now reached the clinical stage. Interestingly, an augmented production of PGI 2 was observed with suppression of mPGES-1-derived PGE 2 .
7 This is consistent with our initial observation with mPGES-1 KO mice. 11 Potential elevation of prostaglandin products because of substrate rediversion may depend on specific tissue/cell or disease pathology. 10 Their significance in mediating the cardiovascular profile of mPGES-1 inhibition relative to COX-2 inhibition warrants future study. Our study here suggests that augmented PGI 2 may balance a vascular risk of suppressing PGE 2 -EP4 axis when mPGES-1 inhibition is pursued under pathological insult.
In conclusion, we have previously provided evidence that inhibition of mPGES-1 may offer an approach adjunctive to percutaneous coronary intervention to limit restenosis because of its capacity to augment PGI 2 . Here, we provide evidence that PGE 2 formation might be targeted to achieve the same objective, here by activating the EP4 receptor in ECs. Given that restenosis remains a restraint on the clinical effectiveness of percutaneous coronary intervention, 40, 41 the provision of preclinical data consistent with 2 distinct strategies by which this might be mitigated is timely.
Study Limitations
This study was conducted with mice of C57BL/6 background. Confirming this study with other mouse strains or other species more relevant to human pathophysiology would help increase the translational potential of the mechanism discovered here.
